A missing data approach to semi-competing risks problems

Statistics in Medicine

Volumn 26, Issue 4, 2007, Pages 837-856

  Dignam, James J ^a   Wieand, Kelly ^a   Rathouz, Paul J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Competing risks; EM algorithm; Identifiability; Survival analysis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PLACEBO; TAMOXIFEN;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIMULATION; SURVIVAL TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; DATA INTERPRETATION, STATISTICAL; DOXORUBICIN; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN;

EID: 33846839250     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2582     Document Type: Article

References (31)

1. Cox DR. The analysis of exponentially distributed life-times with two types of failure. Journal of the Royal Statistical Society, Series B 1959; 21:411-421.
2. Gail MH. A review and critique of some models used in competing risks analysis. Biometrics 1975; 31:209-222.
3. Tsiatis AA. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences 1975; 72:20-22.
4. Peterson AV. Bounds for a joint distribution function with fixed sub-distribution functions: applications to competing risks. Proceedings of the National Academy of Sciences 1976; 73:11-13.
5. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34:541-554.
6. Fine JP, Jiang H, Chappell R. On semi-competing risks data. Biometrika 1999; 88:907-919.
7. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M, Margolese R. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991; 338:327-331.
8. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine 2002; 347:1233-1241.
9. Crowder M. On the identifiability crisis in competing risks analysis. Scandinavian Journal of Statistics 1991; 18:223-233.
10. Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981; 37:67-78.
11. Andersen PK, Borgan O, Gill R, Keiding N. Statistical Methods Based on Counting Processes. Springer: Berlin, 1993.
12. Epstein LD, Muñoz A. A bivariate parametric model for survival and intermediate event times. Statistics in Medicine 1996; 15:1171-1185.
13. Shen Y, Thall P. Parametric likelihoods for multiple non-fatal competing risks and death. Statistics in Medicine 1998; 17:999-1015.
14. Lin DY, Sun W, Ying Z. Nonparametric estimation of the gap time distribution for serial events with censored data. Biometrika 1999; 86:59-70.
15. Schaubel DE, Cai J. Regression methods for gap time hazard functions of sequentially ordered multivariate failure time data. Biometrika 2004; 91:291-303.
16. Day RS, Bryant J, Lefkopolou M. Adaptation of bivariate frailty models for prediction, with application to biological markers as prognostic indicators. Biometrika 1997; 84:45-56.
17. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. Journal of the Royal Statistical Society, Series B 1977; 39:1-38.
18. Louis TA. Finding the observed information matrix when using the EM algorithm. Journal of the Royal Statistical Society, Series B 1982; 44:226-233.
19. Ibrahim JG. Incomplete data in generalized linear models. Journal of the American Statistical Association 1990; 85:765-769.
20. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Springer: Berlin, 2002.
21. Clayton DG. A model for association in bivariate life tables and its application to epidemiological studies of familial tendency in chronic disease epidemiology. Biometrika 1978; 65:141-151.
22. Oakes D. A model for association in bivariate survival data. Journal of the Royal Statistical Society, Series B 1982; 44:414-422.
23. Early Breast Cancer Triallists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467.
24. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumours. New England Journal of Medicine 1989; 320:479-484.
25. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. Journal of the National Cancer Institute 1996; 88:1529-1542.
26. Gail MH, Santner TJ, Brown CC. An analysis of comparative carcinogenesis experiments based on multiple times to tumour. Biometrics 1980; 36:255-266.
27. Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. Journal of Clinical Oncology 1997; 15:1858-1869.
28. Engel J, Eckel R, Aydemir U, Adymer S, Kerr J, Schlesinger-Raab A, Dirschedl P, Holzel D. Determinants and prognosis of locoregional and distant progression in breast cancer. International Journal of Radiation Oncology and Biological Physics 2003; 55:1186-1195.
29. Bryant J, Fisher B, Gunduz N, Costantino J, Emir B. S-phase fraction combined with other patient and tumour characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Research and Treatment 1997; 51:239-253.
30. Oakes D. Bivariate survival models induced by frailties. Journal of the American Statistical Association 1989; 84:487-493.
31. Abramowitz M, Stegun IA (eds). Handbook of Mathematical Functions with Formulas, Graphs, and Mathematical Tables (9th edn). Dover: Mineola, NY, 1972.